Differentiating mTOR inhibitors in renal cell carcinoma

Cancer Treatment Reviews

Volumn 39, Issue 7, 2013, Pages 709-719

  Pal, Sumanta K ^a   Quinn, David I ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Everolimus; MTOR inhibitors; PI3K Akt mTOR pathway; Renal cell carcinoma; Temsirolimus; Treatment

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; TRASTUZUMAB; VASCULOTROPIN RECEPTOR;

ACNE; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANGIOMYOLIPOMA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BREAST METASTASIS; CANCER PROGNOSIS; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPNEA; ENDOMETRIUM CANCER; FATIGUE; HISTOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKOPENIA; LYMPHANGIOLEIOMYOMATOSIS; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTMENOPAUSE; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; TUBEROUS SCLEROSIS;

EVEROLIMUS; MTOR INHIBITORS; PI3K/AKT/MTOR PATHWAY; RENAL CELL CARCINOMA; TEMSIROLIMUS; TREATMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84881558888     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.12.015     Document Type: Review

References (106)

1. Cohen H.T., McGovern F.J. Renal-cell carcinoma. N Engl J Med 2005, 353:2477-2490.
2. Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. N Engl J Med 1996, 335:865-875.
3. Gupta K., Miller J.D., Li J.Z., Russell M.W., Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008, 34:193-205.
4. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
5. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
6. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
7. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
8. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
9. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-5428.
10. Motzer R.J., Escudier B., Oudard S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
11. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
12. Rini B.I., Escudier B., Tomczak P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
13. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
14. Escudier B., Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v137-v139.
15. Ljungberg B., Cowan N.C., Hanbury D.C., et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
16. de Reijke T.M., Bellmunt J., van Poppel H., Marreaud S., Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009, 45:765-773.
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Kidney Cancer (Version 2.2012) 2012. Accessed 8.7.2012. http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
18. Meric-Bernstam F., Gonzalez-Angulo A.M. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009, 27:2278-2287.
19. Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011, 10:868-880.
20. Lebwohl D., Thomas G., Lane H.A., et al. Research and innovation in the development of everolimus for oncology. Expert Opin Drug Discov 2011, 6:323-338.
21. Husseinzadeh H.D., Garcia J.A. Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. Curr Clin Pharmacol 2011, 6:214-221.
22. Pantuck A.J., Seligson D.B., Klatte T., et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007, 109:2257-2267.
23. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 2007, 356:185-187.
24. Robb V.A., Karbowniczek M., Klein-Szanto A.J., Henske E.P. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007, 177:346-352.
25. Cho D., Signoretti S., Regan M., Mier J.W., Atkins M.B. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007, 13:758s-763s.
26. Sabers C.J., Martin M.M., Brunn G.J., et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995, 270:815-822.
27. Beuvink I., Boulay A., Fumagalli S., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120:747-759.
28. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
29. Dancey J.E. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 2006, 5:1065-1073.
30. Bissler J.J., McCormack F.X., Young L.R., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358:140-151.
31. Davies D.M., de Vries P.J., Johnson S.R., et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011, 17:4071-4081.
32. McCormack F.X., Inoue Y., Moss J., et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011, 364:1595-1606.
33. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22:909-918.
34. Hidalgo M., Buckner J.C., Erlichman C., et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5days every 2weeks to patients with advanced cancer. Clin Cancer Res 2006, 12:5755-5763.
35. Chan S., Scheulen M.E., Johnston S., et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005, 23:5314-5322.
36. Hess G., Herbrecht R., Romaguera J., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27:3822-3829.
37. Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:514-523.
38. Dancey J.E., Monzon J. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. Future Oncol 2011, 7:827-839.
39. Ridaforolimus. Drugs RD 2010;10:165-78.
40. Chawla S.P., Sankhala K.K., Chua V., et al. A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas. J Clin Oncol 2005, 23(Suppl. 16 part I of II):9068. [abstract].
41. Grunwald V., DeGraffenried L., Russel D., et al. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002, 62:6141-6145.
42. Dudkin L., Dilling M.B., Cheshire P.J., et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001, 7:1758-1764.
43. Shi Y., Gera J., Hu L., et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002, 62:5027-5034.
44. Geoerger B., Kerr K., Tang C.B., et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001, 61:1527-1532.
45. Yu K., Toral-Barza L., Discafani C., et al. MTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001, 8:249-258.
46. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004, 22:2336-2347.
47. Witzig T.E., Geyer S.M., Ghobrial I., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005, 23:5347-5356.
48. Motzer R.J., Hudes G.R., Curti B.D., et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007, 25:3958-3964.
49. Oza A.M., Elit L., Tsao M.S., et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011, 29:3278-3285.
50. Ansell S.M., Inwards D.J., Rowland K.M., et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008, 113:508-514.
51. Chow L.W.C., Sun Y., Jassem J., et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006, 100(Suppl. 1):S286. [abstract].
52. Torisel® (temsirolimus) 30mg concentrate and diluent for solution for infusion [prescribing information]. Sandwich, Kent, UK: Pfizer Limited; September 2011.
53. Buckner J.C., Forouzesh B., Erlichman C., et al. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest New Drugs 2010, 28:334-342.
54. Carpenter J, Roche H, Campone M, et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. In: Presented at: American Society of Clinical Oncology Annual Meeting; May 13-17, 2005; Orlando, FL.
55. Johnson S.R.D. Role of the mTOR pathway in endocrine resistant breast cancer: opportunities for novel combination strategies. Educational book 2009, American Society of Clinical Oncology, Alexandria, VA.
56. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
57. Wu L., Birle D.C., Tannock I.F. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005, 65:2825-2831.
58. Boulay A., Zumstein-Mecker S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004, 64:252-261.
59. O'Donnell A., Faivre S., Burris H.A., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008, 26:1588-1595.
60. Tanaka C., O'Reilly T., Kovarik J.M., et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008, 26:1596-1602.
61. Tabernero J., Rojo F., Calvo E., et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26:1603-1610.
62. Chan J.A., Ryan D.P., Fuchs C.S., et al. Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET). J Clin Oncol 2011, 29(Suppl.):4120. [abstract].
63. Yao J.C., Lombard-Bohas C., Baudin E., et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010, 28:69-76.
64. Anthony L.B., Peeters M., Hainsworth J.D., et al. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial. J Clin Oncol. 2011, 29(Suppl.):4078. [abstract].
65. Amato R.J., Jac J., Giessinger S., Saxena S., Willis J.P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009, 115:2438-2446.
66. Mayer I.A., Burris H., Bendel J., et al. A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. Cancer Res 2009, 69(Suppl. 3):3093.
67. Ellard S.L., Clemons M., Gelmon K.A., et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009, 27:4536-4541.
68. Andre F., Campone M., O'Regan R., et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010, 28:5110-5115.
69. Dalenc F., Campone M., Hupperets P., et al. Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: a multicenter phase II clinical trial. J Clin Oncol 2010, 28(Suppl.):1013.
70. Jerusalem G., Fasolo A., Dieras V., et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011, 125:447-455.
71. Morrow P.K., Wulf G.M., Ensor J., et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011, 29:3126-3132.
72. Baselga J., Semiglazov V., van Dam P., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2630-2637.
73. Badin F., Romond E., Chambers M., et al. A phase II trial of fulvestrant and RAD001 (everolimus) in patients with metastatic estrogen receptor positive breast cancer after aromatase inhibitor failure; a study in progress. Cancer Res 2010, 70(Suppl. 2). P4-02-05.
74. Bachelot T., Bourgier C., Cropet C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012, 30:2718-2724.
75. Hortobagyi G.N., Piccart M., Rugo H., et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO 2 phase III trial. Cancer Res 2011, 71(Suppl.):S3-S7.
76. Slomovitz B.M., Lu K.H., Johnston T., et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010, 116:5415-5419.
77. Jac J., Giessinger S., Khan M., Willis J., Chiang S., Amato R. A phase II trial of RAD001 in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2007, 25(Suppl.):5107.
78. Afinitor® (everolimus) tablets for oral administration [prescribing information]. Stein, Switzerland: Novartis Pharma Stein; 2010.
79. Afinitor Summary of Product Characteristics [prescribing information]. West Sussex, United Kingdom: Novartis Europharm Limited; September 2011.
80. Clackson T., Metcalf C., Rivera V., et al. Broad anti-tumor activity of AP23573, an mTOR inhibitor in clinical development. Proc Am Soc Clin Oncol 2003, 22:882.
81. Rivera V., Tang H., Metcalf C., et al. Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents. Proc Am Assoc Cancer Res 2004, 45:3887.
82. Mita M.M., Mita A.C., Chu Q.S., et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2weeks to patients with advanced malignancies. J Clin Oncol 2008, 26:361-367.
83. Squillace R.M., Miller D., Cookson M., et al. Antitumor activity of ridaforolimus and potential cell cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther 2011, 10:1959-1968.
84. Rivera V.M., Squillace R.M., Miller D., et al. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther 2011, 10:1059-1071.
85. Perotti A., Locatelli A., Sessa C., et al. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol 2010, 28:4554-4561.
86. Sessa C., Tosi D., Vigano L., et al. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol 2010, 21:1315-1322.
87. Chawla S.P., Blay J., Ray-Coquard I.L., et al. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 2011, 29(Suppl.):10005.
88. Ariad announces oral ridaforolimus achieved primary endpoint of improved progression-free survival in patients with metastatic soft-tissue or bone sarcomas in the phase 3 SUCCEED trial 2011, Merck.com, Merck & Co, Inc., Whitehouse Station, NJ.
89. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5:671-688.
90. Boni J.P., Leister C., Bender G., et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 2005, 77:76-89.
91. Peralba J.M., DeGraffenried L., Friedrichs W., et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003, 9:2887-2892.
92. Lee C.K., Marschner I., Simes J., et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res 2012, 18:3188-3196.
93. Calvo E., Escudier B., Motzer R.J., et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2011, 48:333-339.
94. Yang H., Wong M.K.K., Signorovitch J.E., et al. Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: a retrospective US chart review. J Clin Oncol 2012, 30(Suppl.):4612.
95. Feldman M.E., Apsel B., Uotila A., et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009, 7:e38.
96. Yu K., Shi C., Toral-Barza L., et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 2010, 70:621-631.
97. Yu K., Toral-Barza L., Shi C., et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009, 69:6232-6240.
98. Cho D.C., Cohen M.B., Panka D.J., et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010, 16:3628-3638.
99. Roulin D., Waselle L., Dormond-Meuwly A., et al. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer 2011, 10:90.
100. Burris H., Rodon J., Sharma S., et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol 2010, 28(Suppl.):3005.
101. Yuan J., Mehta P.P., Yin M.J., et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther 2011, 10:2189-2199.
102. Elfiky A.A., Aziz S.A., Conrad P.J., et al. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med 2011, 9:133.
103. Sparks C.A., Guertin D.A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010, 29:3733-3744.
104. Feldman M.E., Shokat K.M. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor kinase domain inhibitors (TORKinibs). Curr Top Microbiol Immunol 2010, 347:241-262.
105. Bracho-Valdes I., Moreno-Alvarez P., Valencia-Martinez I., et al. MTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused. IUBMB Life 2011, 63:880-898.
106. Rho S.B., Song Y.J., Lim M.C., et al. Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell Signal 2012, 24:131-139.